{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:45:38Z","timestamp":1761540338314},"reference-count":26,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2001,12,21]],"date-time":"2001-12-21T00:00:00Z","timestamp":1008892800000},"content-version":"vor","delay-in-days":354,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p>In developed countries, preferred treatments for both haemophilia A and B have moved toward recombinant clotting factor concentrates, while plasma\u2010derived replacement therapies are still required by many patients. Great improvements have been made in producing relatively pathogen\u2010free clotting factor replacements from pooled plasma. The fluidity and complexity of the worldwide plasma product market are discussed in the context of the \u2018yin and yang\u2019 of plasma therapeutics, showing how multiple issues can influence the safety and availability of clotting factor concentrates. Use of plasma\u2010derived products will likely continue for the next decade for patients with inhibitors, patients with von Willebrand disease, those requiring bypassing agents, in immune tolerance induction, and for treatment of rare inherited deficiencies of procoagulant or anticoagulant proteins. Furthermore, in developing countries many of the most advanced therapies are not available for the majority of haemophilia patients, and thus plasma\u2010derived replacement concentrates will continue to be used even for noninhibitor patients.<\/jats:p>","DOI":"10.1046\/j.1365-2516.2001.00099.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:06:29Z","timestamp":1047423989000},"page":"4-9","source":"Crossref","is-referenced-by-count":12,"title":["The future of plasma\u2010derived clotting factor concentrates"],"prefix":"10.1111","volume":"7","author":[{"given":"W.K.","family":"Hoots","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood.V79.3.826.826","article-title":"Solvent\/detergent treated plasma: a virus substitute for fresh frozen plasma.","volume":"79","author":"Horowitz B","year":"1992","journal-title":"Blood"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1993.tb03055.x"},{"key":"e_1_2_6_4_2","unstructured":"The Advisory Committee on Blood Safety and Availability to the U. S. Secretary of Health and Human Services.August 27\u201328 1998 Washington D.C."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-0331-2_12"},{"key":"e_1_2_6_6_2","first-page":"647","article-title":"Analysis of factor VIII inhibitors using hybrid human\/porcine factor VIII.","volume":"8","author":"Lollar P.","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_7_2","unstructured":"LeeM.Presented at \u2018Future Therapies of Hemophilia Care in the New Millennium\u2019 Chapel Hill NC April 8 1999."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615388"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30790385521.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00032.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00034.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830350312"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1055\/s-0037-1614918","article-title":"Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor.","volume":"82","author":"Peerlink K","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615357"},{"key":"e_1_2_6_15_2","first-page":"S61","article-title":"Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high\u2010dose activated factor VII.","volume":"9","author":"Hoffman M","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_6_16_2","unstructured":"KreuzWEuropean and German PUP study presented at the meeting of the International Registry of Immune Tolerance Induction (ITI). Palermo Italy October 1999[abstract]."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197705000-00003"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649667"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1995.35495216081.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830400310"},{"key":"e_1_2_6_21_2","first-page":"321: 1148","article-title":"Absence of anti\u2010human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia and von Willebrand disease with pasteurized factor VIII concentrate.","volume":"26","author":"Schimpf K","year":"1989","journal-title":"N Engl J Med"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1989.tb01244.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1997.tb123269.x"},{"key":"e_1_2_6_24_2","first-page":"320: 403","article-title":"Prospective investigation of transfusion transmitted infection in recipients of over 20,000 units of blood. TTI Study Group.","volume":"12","author":"Regan FA","year":"2000","journal-title":"Br Med J"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood.V79.3.826.826","article-title":"Solvent detergent\u2010treated plasma: a virus\u2010inactivated substitute for fresh frozen plasma.","volume":"79","author":"Horowitz B","year":"1992","journal-title":"Blood"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-7963(99)80002-9"},{"key":"e_1_2_6_27_2","unstructured":"BuschM.Estimates of residual risk in infectious disease transmission during the window period. Presented at Workshop on Implementation of Nucleic Acid Testing. E Tabor Presiding Masur Auditorium NIH Bethesda MD December 14 1999. U.S. Department of Health and Human Services.Public Health Service Food and Drug Administration. Center for Biologics Evaluation and Research. 01\u201012\u20100 http:\/\/www.fda.gov\/cber\/minutes\/nucleic121499.pdf."}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2001.00099.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2001.00099.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2516.2001.00099.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T07:59:18Z","timestamp":1695801558000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2516.2001.00099.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":26,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1046\/j.1365-2516.2001.00099.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2516.2001.00099.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}